After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. The company on Tuesday will cut the ribbon on its new 100,086 square-foot headquarters in Seattle’s… Read More
— Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC. The blank check company is called CM Life Sciences III… Read More
Adaptive Biotechnologies’ revenue fell 5% to $21 million in the second quarter, and its net loss more than doubled to $33.5 million, due in part to reduced usage of its… Read More
Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third-quarter earnings.… Read More
Adaptive Biotechnologies is charting a massive expansion of its Seattle headquarters following the completion of a recent initial public offering. The company signed a 100,000 square-foot lease, tripling its current… Read More
Adaptive Biotechnologies had a heck of a first day as a public company. Shares of the Seattle-based biotech, which makes technology to diagnose and treat diseases by reading the immune… Read More
Follow-up: Big debut: Shares of Adaptive Biotechnologies rise 100% on first day as public company The public market is bullish on Adaptive Biotechnologies. The biotech company started trading on the… Read More
Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company,… Read More
Dr. Harlan Robins, co-founder and chief scientific officer of Seattle-based Adaptive Biotechnologies, stepped down from his role as head of the computational biology program at the Fred Hutchinson Cancer Research… Read More
— The former head of Juno Therapeutics, Hans Bishop, signed on as CEO of Grail, a Bay Area biotech focused on the early detection of cancer. Bishop replaces former Grail… Read More